No Data
No Data
Korro Bio Initiated With an Overweight at Cantor Fitzgerald
Chardan Capital Initiates Korro Bio(KRRO.US) With Buy Rating, Announces Target Price $25
This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Express News | Korro Bio Inc : Chardan Capital Markets Initiates Coverage With Buy Rating; Price Target $25
Press Release: Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer
Korro Bio CFO Resumes Role After Temporary Medical Leave